Intravenous Iron Repletion in Patients With Continuous-Flow Left Ventricular Assist Devices
- PMID: 36228660
- DOI: 10.1097/MAT.0000000000001800
Intravenous Iron Repletion in Patients With Continuous-Flow Left Ventricular Assist Devices
Conflict of interest statement
Disclosure: T.D.B., G.S., J.L.V., and H.K.S. do not have any conflict of interest to disclose with respect to this work. M.R.M. has received consulting fees from Abbott Medtronic, Janssen (a division of Johnson and Johnson), Natera, Baim Institute for Clinical Research, and Paragonix, participation on a data safety monitoring board or advisory board for Mesoblast, and reports holding stock or stock options in NupulseCV, Leviticus, and Fineheart.
References
-
- Amione-Guerra J, Cruz-Solbes AS, Bhimaraj A, et al.: Anemia after continuous-flow left ventricular assist device implantation: characteristics and implications. Int J Artif Organs 40: 481–488, 2017.
-
- Mondal NK, Chen Z, Trivedi JR, et al.: Association of oxidative stress and platelet receptor glycoprotein GPIbα and GPVI shedding during nonsurgical bleeding in heart failure patients with continuous-flow left ventricular assist device support. ASAIO J 64: 462–471, 2018.
-
- Shah AA, Donovan K, Seeley C, et al.: Risk of infection associated with administration of intravenous iron: a systematic review and meta-analysis. JAMA Netw Open 4: e2133935, 2021.
-
- Patel CB, Blue L, Cagliostro B, et al.: Left ventricular assist systems and infection-related outcomes: a comprehensive analysis of the MOMENTUM 3 trial. J Heart Lung Transplant 39: 774–781, 2020.
-
- Anker SD, Comin Colet J, Filippatos G, et al.; FAIR-HF Trial Investigators: Ferric carboxymaltose in patients with heart failure and iron deficiency. N Engl J Med 361: 2436–2448, 2009.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical